IRCT20200105046010N51
Recruiting
未知
in- Vivo Bioequivalence study of Erlotinib tablet 150 mg Abidi Pharma (LOTIVA® 150 mg) with brand drug (TARCEVA® 150 mg, Rosche, Switzerland) in Iranian healthy volunteers.
Abidi Pharmaceutical Company0 sites24 target enrollmentStarted: TBDLast updated:
ConditionsBio equivalence test.
Overview
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Abidi Pharmaceutical Company
- Enrollment
- 24
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- All
Inclusion Criteria
- •General health
- •Body mass index between18\-28
- •Informed consent
- •Being at the age of 18\-55 years old
Exclusion Criteria
- •A history of cardiovascular disease
- •A history of liver \& kidney disease
- •Alcohol \& Drug addiction
- •Hypersensitivity to the drug
Investigators
Similar Trials
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
Completed
Not Applicable
Bioequivalence study of erlotinib 150 mgIRCT20200623047902N6Zistdaru Danesh Company24
Not yet recruiting
Not Applicable
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24